SI-BONE, Inc. (NASDAQ:SIBN) Shares Bought by Kent Lake Capital LLC

Kent Lake Capital LLC lifted its position in SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 33.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 400,000 shares of the company's stock after acquiring an additional 100,000 shares during the quarter. SI-BONE accounts for approximately 3.2% of Kent Lake Capital LLC's investment portfolio, making the stock its 14th largest holding. Kent Lake Capital LLC owned approximately 0.99% of SI-BONE worth $8,396,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Coppell Advisory Solutions LLC bought a new position in SI-BONE in the second quarter worth about $50,000. FMR LLC grew its stake in shares of SI-BONE by 28.7% during the first quarter. FMR LLC now owns 2,160 shares of the company's stock worth $42,000 after acquiring an additional 482 shares during the last quarter. Comerica Bank purchased a new stake in shares of SI-BONE during the third quarter worth about $47,000. RiverPark Advisors LLC purchased a new stake in shares of SI-BONE during the third quarter worth about $55,000. Finally, Lazard Asset Management LLC purchased a new stake in shares of SI-BONE during the second quarter worth about $70,000. 98.11% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on SIBN shares. Cantor Fitzgerald restated an "overweight" rating and set a $25.00 price target on shares of SI-BONE in a research note on Tuesday, February 27th. Truist Financial restated a "buy" rating and set a $24.00 price target (down previously from $26.00) on shares of SI-BONE in a research note on Tuesday, February 27th. Morgan Stanley upped their target price on SI-BONE from $25.00 to $26.00 and gave the company an "overweight" rating in a research report on Tuesday, February 27th. Needham & Company LLC reiterated a "buy" rating and issued a $27.00 target price on shares of SI-BONE in a research report on Wednesday. Finally, Piper Sandler initiated coverage on SI-BONE in a research report on Thursday, March 28th. They issued an "overweight" rating and a $25.00 target price on the stock. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $26.67.

SI-BONE Stock Performance

NASDAQ:SIBN traded down $0.04 during trading hours on Friday, reaching $15.36. The company had a trading volume of 267,749 shares, compared to its average volume of 457,475. SI-BONE, Inc. has a 1-year low of $14.88 and a 1-year high of $29.51. The firm has a market cap of $630.76 million, a PE ratio of -13.47 and a beta of 1.20. The business's 50 day moving average price is $18.22 and its 200-day moving average price is $18.73. The company has a debt-to-equity ratio of 0.21, a current ratio of 9.01 and a quick ratio of 8.15.

SI-BONE (NASDAQ:SIBN - Get Free Report) last announced its quarterly earnings results on Monday, February 26th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.02. SI-BONE had a negative return on equity of 28.22% and a negative net margin of 31.20%. The company had revenue of $38.86 million during the quarter, compared to the consensus estimate of $38.60 million. Research analysts forecast that SI-BONE, Inc. will post -0.98 EPS for the current year.

Insider Transactions at SI-BONE

In other news, CFO Anshul Maheshwari sold 2,425 shares of the company's stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $15.45, for a total transaction of $37,466.25. Following the completion of the transaction, the chief financial officer now directly owns 205,516 shares of the company's stock, valued at approximately $3,175,222.20. The sale was disclosed in a filing with the SEC, which is available at this link. In related news, CFO Anshul Maheshwari sold 2,425 shares of the stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $15.45, for a total value of $37,466.25. Following the completion of the transaction, the chief financial officer now directly owns 205,516 shares of the company's stock, valued at approximately $3,175,222.20. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Mika Nishimura sold 2,500 shares of the stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $16.22, for a total value of $40,550.00. Following the completion of the transaction, the director now directly owns 19,350 shares of the company's stock, valued at $313,857. The disclosure for this sale can be found here. Insiders sold a total of 11,562 shares of company stock valued at $185,285 in the last three months. 5.40% of the stock is currently owned by company insiders.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.